{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T00:19:06Z","timestamp":1792887546731,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"S2","license":[{"start":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T00:00:00Z","timestamp":1698364800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T00:00:00Z","timestamp":1698364800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"DOI":"10.1186\/s13023-023-02883-3","type":"journal-article","created":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T23:02:32Z","timestamp":1698361352000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["XLH Matters 2022: Insights and recommendations to improve outcomes for people living with X-linked hypophosphataemia (XLH)"],"prefix":"10.1186","volume":"18","author":[{"given":"Lothar","family":"Seefried","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Alzahrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Arango Sancho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Bacchetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Crowley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Emma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Gibbins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Grandone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Kassim","family":"Javaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Mindler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adalbert","family":"Raimann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anya","family":"Rothenbuhler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Tucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonid","family":"Zeitlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Linglart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,27]]},"reference":[{"key":"2883_CR1","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13023-019-1014-8","volume":"14","author":"SS Beck-Nielsen","year":"2019","unstructured":"Beck-Nielsen SS, et al. FGF23 and its role in X-linked hypophosphatemia-related morbidity. Orphanet J Rare Dis. 2019;14:58.","journal-title":"Orphanet J Rare Dis"},{"key":"2883_CR2","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41581-019-0152-5","volume":"15","author":"D Haffner","year":"2019","unstructured":"Haffner D, et al. Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat Rev Nephrol. 2019;15:435\u201355.","journal-title":"Nat Rev Nephrol"},{"key":"2883_CR3","doi-asserted-by":"publisher","first-page":"bvab070","DOI":"10.1210\/jendso\/bvab070","volume":"5","author":"M Cheung","year":"2021","unstructured":"Cheung M, et al. Patient-reported complications, symptoms, and experiences of living with X-linked hypophosphatemia across the life-course. J Endocr Soc. 2021;5:bvab070.","journal-title":"J Endocr Soc"},{"key":"2883_CR4","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1210\/js.2018-00365","volume":"3","author":"A Skrinar","year":"2019","unstructured":"Skrinar A, et al. The lifelong impact of X-linked hypophosphatemia: results from a burden of disease survey. J Endocr Soc. 2019;3:1321\u201334.","journal-title":"J Endocr Soc"},{"key":"2883_CR5","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1007\/s10354-019-00732-2","volume":"170","author":"A Raimann","year":"2020","unstructured":"Raimann A, et al. Multidisciplinary patient care in X-linked hypophosphatemic rickets: one challenge, many perspectives. Wien Med Wochenschr. 2020;170:116\u201323.","journal-title":"Wien Med Wochenschr"},{"key":"2883_CR6","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.arcped.2021.09.005","volume":"28","author":"NAT Hamdy","year":"2021","unstructured":"Hamdy NAT, et al. X-linked hypophosphatemia: the medical expert\u2019s challenges and the patient\u2019s concerns on their journey with the disease. Arch Pediatr. 2021;28:612\u20138.","journal-title":"Arch Pediatr"},{"key":"2883_CR7","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1007\/s12325-019-01193-0","volume":"37","author":"N Ferizovic","year":"2020","unstructured":"Ferizovic N, et al. Exploring the burden of X-linked hypophosphataemia: an opportunistic qualitative study of patient statements generated during a technology appraisal. Adv Ther. 2020;37:770\u201384.","journal-title":"Adv Ther"},{"key":"2883_CR8","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.1093\/rheumatology\/keaa859","volume":"60","author":"S Hawley","year":"2021","unstructured":"Hawley S, et al. Higher prevalence of non-skeletal comorbidity related to X-linked hypophosphataemia: a UK parallel cohort study using CPRD. Rheumatology. 2021;60:4055\u201362.","journal-title":"Rheumatology"},{"key":"2883_CR9","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1007\/s00198-021-05997-1","volume":"32","author":"S Giannini","year":"2021","unstructured":"Giannini S, et al. Burden of disease and clinical targets in adult patients with X-linked hypophosphatemia. A comprehensive review. Osteoporos Int. 2021;32:1937\u201349.","journal-title":"Osteoporos Int"},{"key":"2883_CR10","doi-asserted-by":"crossref","unstructured":"Arancho Sancho P, et al. Complications of phosphate and vitamin D treatment in X-linked hypophosphataemia. Adv Ther. 2020;37:105\u201312.","DOI":"10.1007\/s12325-019-01170-7"},{"key":"2883_CR11","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/s41574-022-00662-x","volume":"18","author":"A Trombetti","year":"2022","unstructured":"Trombetti A, et al. Interdisciplinary management of FGF23-related phosphate wasting syndromes: a consensus statement on the evaluation, diagnosis and care of patients with X-linked hypophosphataemia. Nat Rev Endocrinol. 2022;18:366\u201384.","journal-title":"Nat Rev Endocrinol"},{"key":"2883_CR12","doi-asserted-by":"publisher","first-page":"bvaa151","DOI":"10.1210\/jendso\/bvaa151","volume":"4","author":"K Dahir","year":"2020","unstructured":"Dahir K, et al. X-linked hypophosphataemia: a new era in management. J Endocr Soc. 2020;4:bvaa151.","journal-title":"J Endocr Soc"},{"key":"2883_CR13","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1002\/jbmr.3614","volume":"34","author":"A Rothenbuhler","year":"2019","unstructured":"Rothenbuhler A, et al. High incidence of cranial synostosis and Chiari I malformation in children with X-linked hypophosphatemic rickets (XLHR). J Bone Miner Res. 2019;34:490\u20136.","journal-title":"J Bone Miner Res"},{"key":"2883_CR14","doi-asserted-by":"publisher","first-page":"R13","DOI":"10.1530\/EC-13-0103","volume":"3","author":"A Linglart","year":"2014","unstructured":"Linglart A, et al. Therapeutic management of hypophosphatemic rickets from infancy to adulthood. Endocr Connect. 2014;3:R13-30.","journal-title":"Endocr Connect"},{"key":"2883_CR15","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s00467-011-2046-z","volume":"27","author":"C Quinlan","year":"2012","unstructured":"Quinlan C, et al. Growth in PHEX-associated X-linked hypophosphatemic rickets: the importance of early treatment. Pediatr Nephrol. 2012;27:581\u20138.","journal-title":"Pediatr Nephrol"},{"key":"2883_CR16","doi-asserted-by":"publisher","first-page":"3243","DOI":"10.1210\/clinem\/dgaa495","volume":"105","author":"M Mao","year":"2020","unstructured":"Mao M, et al. Growth curves for children with X-linked hypophosphatemia. J Clin Endocrinol Metab. 2020;105:3243\u20139.","journal-title":"J Clin Endocrinol Metab"},{"key":"2883_CR17","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.1210\/jc.2003-030036","volume":"88","author":"O M\u00e4kitie","year":"2003","unstructured":"M\u00e4kitie O, et al. Early treatment improves growth and biochemical and radiographic outcome in X-linked hypophosphatemic rickets. J Clin Endocrinol Metab. 2003;88:3591\u20137.","journal-title":"J Clin Endocrinol Metab"},{"key":"2883_CR18","doi-asserted-by":"publisher","DOI":"10.1530\/EC-21-0564","volume":"11","author":"C Nguyen","year":"2022","unstructured":"Nguyen C, et al. Oral health-related quality of life in patients with X-linked hypophosphatemia: a qualitative exploration. Endocr Connect. 2022;11:e210564.","journal-title":"Endocr Connect"},{"key":"2883_CR19","doi-asserted-by":"publisher","first-page":"e1249","DOI":"10.1210\/clinem\/dgab739","volume":"107","author":"MK Javaid","year":"2022","unstructured":"Javaid MK, et al. Musculoskeletal features in adults with X-linked hypophosphatemia: an analysis of clinical trial and survey data. J Clin Endocrinol Metab. 2022;107:e1249\u201362.","journal-title":"J Clin Endocrinol Metab"},{"key":"2883_CR20","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1530\/EJE-15-0661","volume":"174","author":"H Che","year":"2016","unstructured":"Che H, et al. Impaired quality of life in adults with X-linked hypophosphatemia and skeletal symptoms. Eur J Endocrinol. 2016;174:325\u201333.","journal-title":"Eur J Endocrinol"},{"key":"2883_CR21","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.jbspin.2019.01.012","volume":"86","author":"AS Lambert","year":"2019","unstructured":"Lambert AS, et al. X-linked hypophosphatemia: management and treatment prospects. Joint Bone Spine. 2019;86:731\u20138.","journal-title":"Joint Bone Spine"},{"key":"2883_CR22","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s40272-020-00381-8","volume":"22","author":"V Saraff","year":"2020","unstructured":"Saraff V, et al. New developments in the treatment of X-linked hypophosphataemia: implications for clinical management. Paediatr Drugs. 2020;22:113\u201321.","journal-title":"Paediatr Drugs"},{"key":"2883_CR23","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1016\/S0140-6736(19)30654-3","volume":"393","author":"E Imel","year":"2019","unstructured":"Imel E, et al. Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. Lancet. 2019;393:2416\u201327.","journal-title":"Lancet"},{"key":"2883_CR24","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00223-019-00568-3","volume":"105","author":"A Portale","year":"2019","unstructured":"Portale A, et al. Continued beneficial effects of burosumab in adults with X-linked hypophosphatemia: results from a 24-week treatment continuation period after a 24\u2013week double-blind placebo-controlled period. Calcif Tissue Int. 2019;105:271\u201384.","journal-title":"Calcif Tissue Int"},{"key":"2883_CR25","doi-asserted-by":"publisher","first-page":"e10692","DOI":"10.1002\/jbm4.10692","volume":"6","author":"KM Dahir","year":"2022","unstructured":"Dahir KM, et al. X-linked hypophosphatemia caused by the prevailing North American PHEX variant c.*231A>G; Exon 13\u201315 duplication is often misdiagnosed as ankylosing spondylitis and manifests in both men and women. JBMR Plus. 2022;6:e10692.","journal-title":"JBMR Plus"},{"key":"2883_CR26","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s00198-020-05548-0","volume":"32","author":"L Seefried","year":"2021","unstructured":"Seefried L, et al. Burden of disease associated with X-linked hypophosphataemia in adults: a systematic literature review. Osteoporos Int. 2021;32:7\u201322.","journal-title":"Osteoporos Int"},{"key":"2883_CR27","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1007\/s11136-020-02465-x","volume":"29","author":"SH Lo","year":"2020","unstructured":"Lo SH, et al. Exploring the burden of X-linked hypophosphatemia: a European multi-country qualitative study. Qual Life Res. 2020;29:1883\u201393.","journal-title":"Qual Life Res"},{"key":"2883_CR28","doi-asserted-by":"publisher","first-page":"411","DOI":"10.3390\/endocrines3030032","volume":"3","author":"T Kubota","year":"2022","unstructured":"Kubota T, et al. X-linked hypophosphatemia transition and team management. Endocrines. 2022;3:411\u20138.","journal-title":"Endocrines"},{"key":"2883_CR29","unstructured":"NICE NG43. Transition from children\u2019s to adults\u2019 services for young people using health or social care services. Available at: www.nice.org.uk\/guidance\/ng43. Accessed: July 2023."},{"key":"2883_CR30","doi-asserted-by":"publisher","first-page":"1034580","DOI":"10.3389\/fendo.2022.1034580","volume":"13","author":"MZ Mughal","year":"2023","unstructured":"Mughal MZ, et al. Burosumab for X-linked hypophosphataemia in children and adolescents: opinion based on early experience in seven European countries. Front Endocrinol. 2023;13:1034580.","journal-title":"Front Endocrinol"},{"key":"2883_CR31","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1210\/clinem\/dgab796","volume":"3","author":"K Dahir","year":"2022","unstructured":"Dahir K, et al. Health care transition from pediatric- to adult-focused care in X-linked hypophosphatemia: expert consensus. J Clin Endocrinol Metab. 2022;3:599\u2013613.","journal-title":"J Clin Endocrinol Metab"},{"key":"2883_CR32","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s40272-020-00414-2","volume":"5","author":"BR Campagna","year":"2020","unstructured":"Campagna BR. Adherence to medication during transition to adult services. Paediatr Drugs. 2020;5:501\u20139.","journal-title":"Paediatr Drugs"},{"key":"2883_CR33","unstructured":"Kyowa Kirin Limited. CRYSVITA (burosumab). Summary of Product Characteristics."},{"key":"2883_CR34","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1007\/s00223-020-00797-x","volume":"108","author":"R Padidela","year":"2021","unstructured":"Padidela R, et al. Patient-reported outcomes from a randomized, active-controlled, open-label, phase 3 trial of burosumab versus conventional therapy in children with X-linked hypophosphatemia. Calcif Tissue Int. 2021;108:622\u201333.","journal-title":"Calcif Tissue Int"},{"key":"2883_CR35","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1002\/jbmr.3843","volume":"34","author":"KL Insogna","year":"2019","unstructured":"Insogna KL, et al. Burosumab improved histomorphometric measures of osteomalacia in adults with X-linked hypophosphatemia: a phase 3, single-arm, international trial. J Bone Miner Res. 2019;34:2183\u201391.","journal-title":"J Bone Miner Res"},{"key":"2883_CR36","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1210\/clinem\/dgab729","volume":"107","author":"A Linglart","year":"2022","unstructured":"Linglart A, et al. Sustained efficacy and safety of burosumab, a monoclonal antibody to FGF23, in children with X-linked hypophosphatemia. J Clin Endocrinol Metab. 2022;107:813\u201324.","journal-title":"J Clin Endocrinol Metab"},{"key":"2883_CR37","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002676","volume":"9","author":"P Kamenicky","year":"2023","unstructured":"Kamenicky P, et al. Benefit of burosumab in adults with X-linked hypophosphataemia (XLH) is maintained with long-term treatment. RMD Open. 2023;9:e002676.","journal-title":"RMD Open"},{"key":"2883_CR38","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s13023-020-01434-4","volume":"15","author":"R Padidela","year":"2020","unstructured":"Padidela R, et al. The international X-linked hypophosphataemia (XLH) registry (NCT03193476): rationale for and description of an international, observational study. Orphanet J Rare Dis. 2020;15:172.","journal-title":"Orphanet J Rare Dis"},{"key":"2883_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.832063","volume":"13","author":"S K\u00f6lker","year":"2022","unstructured":"K\u00f6lker S, et al. Rare disease registries are key to evidence-based personalized medicine: highlighting the European experience. Front Endocrinol. 2022;13:832063.","journal-title":"Front Endocrinol"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-02883-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-023-02883-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-02883-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T23:02:44Z","timestamp":1698361364000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-023-02883-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,27]]},"references-count":39,"journal-issue":{"issue":"S2","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["2883"],"URL":"https:\/\/doi.org\/10.1186\/s13023-023-02883-3","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,27]]},"assertion":[{"value":"27 October 2023","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"333"}}